List of Excipients in Branded Drug LACTULOSE SOLUTION

Generic Drugs Containing LACTULOSE SOLUTION

Company	Ingredient	NDC	Excipient
Bajaj Medical LLC	lactulose solution usp, 10 g/15 ml	61037-471	D&C YELLOW NO. 10
Bajaj Medical LLC	lactulose solution usp, 10 g/15 ml	61037-471	FD&C YELLOW NO. 6
Bajaj Medical LLC	lactulose solution usp, 10 g/15 ml	61037-471	WATER
Rising Pharma Holdings Inc	lactulose solution usp, 10 g/15 ml	64980-592	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in LACTULOSE SOLUTION?

# Of NDCs	Excipient
3	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
4	FD&C YELLOW NO. 6
1	GALACTOSE

Lactulose Solution Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

Lactulose solution is a mature, low-barrier oral drug with limited conventional patent protection. Commercial value is concentrated in manufacturing cost, taste masking, packaging, dosing convenience, supply reliability, and differentiated formulations rather than in new chemical-entity exclusivity.

The standard product is an aqueous solution containing 10 g of lactulose per 15 mL. In the United States, lactulose is used by prescription for portal-systemic encephalopathy and constipation. FDA-approved labeling identifies the active ingredient as a synthetic disaccharide and describes common solution components and sugar-related impurities, including galactose and lactose [1].

What is the FDA regulatory status of lactulose solution?

Lactulose solution is an FDA-approved oral drug available primarily as a generic prescription product in the United States.

Regulatory attribute	United States position
Active ingredient	Lactulose
Common strength	10 g per 15 mL
Dosage form	Oral solution
Main labeled uses	Portal-systemic encephalopathy; constipation
Approval pathway	Abbreviated New Drug Application for generic products; historical NDA approval for the reference product
Prescription status	Prescription
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Controlled substance status	Not controlled
Orange Book relevance	Product and therapeutic-equivalence listings are relevant; biologic interchangeability provisions are not
Pediatric use	Labeling depends on indication and product labeling

Lactulose acts locally in the colon after limited systemic absorption. Bacterial metabolism produces organic acids, lowers colonic pH, increases osmotic water retention, and softens stool. In hepatic encephalopathy, acidification of colonic contents supports conversion of ammonia to ammonium and promotes nitrogen excretion [1,2].

Commercial development must distinguish between the two principal use cases. Constipation is a high-volume, convenience-driven market. Hepatic encephalopathy is a lower-volume, clinically supervised market in which dose titration, adherence, and reliable delivery are more important than consumer branding.

What excipients are used in lactulose solution?

The primary excipient is purified water. Lactulose itself is supplied as an aqueous solution or concentrated syrup, so the formulation has fewer excipient design variables than a tablet, capsule, or suspension.

Common formulation constituents and related substances include:

Component	Formulation role or significance
Purified water	Vehicle
Lactulose	Active osmotic disaccharide
Galactose	Process-related or residual sugar component
Lactose	Residual sugar component
Fructose	Residual sugar component
Epilactose and related sugars	Process-related impurities
Citric acid or other acidulants	Possible pH adjustment, depending on product
Flavoring agents	Taste improvement in selected products
Coloring agents	Product identification or consumer acceptability
Preservatives	May be used in some presentations but are not necessarily required in every formulation

The excipient strategy is constrained by the chemistry of the active ingredient. Lactulose products can contain substantial concentrations of sugars and related carbohydrates. A formulation marketed as "sugar-free" in the conventional nutritional sense would be difficult to support because lactulose is itself a synthetic sugar and may be accompanied by residual mono- and disaccharides.

Product-specific inactive ingredients must be confirmed in the current FDA label, DailyMed entry, or approved application. Generic manufacturers should not assume that the excipient profile of one lactulose solution applies to another [1,3].

What formulation patents protect lactulose solution?

Lactulose solution has limited visible patent differentiation in the United States because the active ingredient and conventional aqueous dosage form are long established.

The principal protection categories are:

1. Process patents covering lactulose production, purification, crystallization, or impurity control.
2. Formulation patents covering taste masking, preservation, modified concentration, or specialized packaging.
3. Method-of-use patents covering constipation, hepatic encephalopathy, or dosing regimens.
4. Manufacturing know-how involving color control, degradation management, and batch consistency.

The standard 10 g/15 mL aqueous product is unlikely to support meaningful new-product exclusivity solely through the use of purified water and conventional flavoring. Patent value would be stronger where a formulation demonstrates a measurable technical advantage, such as improved stability, lower impurity levels, reduced crystallization, improved dose uniformity, or a clinically meaningful adherence benefit.

What is the Orange Book status of lactulose solution?

The Orange Book should be reviewed by product number, applicant, and dosage form because listings can change as reference products and generic approvals evolve [4]. Lactulose products generally present a low Orange Book patent risk compared with recently approved small-molecule drugs.

The commercial implications are:

• A generic applicant is more likely to encounter chemistry, manufacturing, and controls requirements than a meaningful patent barrier.
• Paragraph IV litigation is not the normal central risk for a mature lactulose solution unless a specific listed patent is identified.
• Any patent analysis must separate the historical reference product from current generic labels.
• A patent covering a delivery package, flavor system, or special indication may not block standard oral-solution entry.

When does lactulose solution lose exclusivity?

Lactulose lost meaningful composition-of-matter exclusivity long ago. The current market is defined by generic competition and regulatory approval rather than by an approaching loss of basic patent exclusivity.

Exclusivity category	Commercial status
New chemical entity exclusivity	Expired or not relevant to current generic entry
Orphan-drug exclusivity	Not a general feature of lactulose solution
Pediatric exclusivity	Not a principal current market barrier
Reference-product exclusivity	Historical and product-specific
Formulation exclusivity	Possible only for separately protected innovations
Manufacturing exclusivity	Usually based on trade secrets and process capability
Generic entry barrier	Primarily FDA approval, product quality, supply, and reimbursement

There is no biosimilar exposure because lactulose is a small-molecule carbohydrate drug, not a therapeutic protein. The relevant competitive threat is generic substitution and private-label distribution.

What excipient strategies can differentiate lactulose solution?

Taste and adherence optimization

Lactulose is widely associated with a sweet, viscous, and sometimes unpleasant taste. Taste improvement is the clearest consumer-facing opportunity.

Potential approaches include:

• Fruit flavors compatible with acidic aqueous systems.
• Lower-intensity flavor systems that avoid masking one unpleasant note with another.
• Sweetness balancing without excessive viscosity.
• Flavor systems designed for dilution in water, juice, or milk.
• Single-dose sachets that reduce repeated exposure to the bottle taste.

Flavor development must preserve chemical stability and avoid interactions with lactulose or packaging materials. Flavoring may also create regulatory complexity if the product is positioned for pediatric use.

Unit-dose and adherence formats

Lactulose is usually titrated to bowel response or to achieve a target stool frequency in hepatic encephalopathy. A multi-dose bottle is inexpensive but creates dosing and portability problems.

Commercially attractive formats include:

• 15 mL unit-dose cups.
• Premeasured oral syringes.
• Sachets or stick packs.
• Small-volume travel bottles.
• Hospital-ready cups with tamper-evident seals.
• Patient packs combining a measuring device with written titration instructions.

Unit-dose packaging can reduce dosing errors and improve pharmacy and hospital workflow. The tradeoff is higher packaging cost and greater material consumption.

Viscosity and pourability

Lactulose solutions can be thick and difficult to pour accurately. A formulation that maintains adequate concentration while improving pourability could support a differentiated product.

Relevant development targets include:

• Consistent dose delivery at low temperatures.
• Reduced residue on bottle walls.
• Lower foaming during filling.
• Improved compatibility with oral syringes.
• Reduced crystallization or precipitation during storage.

Any viscosity change must be evaluated against delivered dose, microbial quality, patient acceptability, and container-closure performance.

Preservative strategy

An aqueous oral solution can create microbiological control challenges. A preservative-free presentation may be commercially attractive for patients who are sensitive to preservatives, but it requires an appropriate container-closure system, validated manufacturing controls, and stability data.

Possible strategies include:

• Preservative-containing multidose bottles.
• Preservative-free unit-dose containers.
• Blow-fill-seal or other high-integrity packaging.
• Reduced headspace and tamper-evident closures.
• Packaging designed to limit repeated microbial ingress.

The strongest opportunity is often packaging-led rather than excipient-led. A preservative-free claim without a validated microbial-control strategy would not support approval or reliable commercialization.

What manufacturing and intellectual-property barriers affect lactulose solution?

Lactulose is produced by chemical or enzymatic conversion of lactose-derived feedstocks, followed by purification and concentration. Manufacturing performance depends on control of residual sugars, color, degradation products, and batch-to-batch concentration.

Key barriers include:

Barrier	Commercial effect
Feedstock quality	Affects impurity profile and yield
Purification capacity	Influences cost and regulatory consistency
Color formation	Can affect appearance and market acceptance
Residual lactose and galactose	Requires specification and labeling control
Concentration control	Determines delivered dose
Microbial control	Critical for aqueous products
Container compatibility	Affects leakage, adsorption, and shelf life
Supply concentration	Determines shipping economics
Global specifications	May differ across USP, Ph. Eur., and other standards

Trade secrets may provide more practical protection than patents. A supplier with a stable low-color lactulose concentrate, strong impurity control, and validated long-term supply may have an advantage even without enforceable exclusivity.

Which companies are challenging lactulose solution?

The market is fragmented among generic manufacturers, contract manufacturers, pharmacy suppliers, and regional distributors. Major branded innovation-company competition is limited.

Competition typically occurs through:

• Generic ANDA approvals.
• Hospital and institutional contracts.
• Pharmacy wholesaler supply.
• Private-label products.
• Regional licensing and distribution.
• Differentiated packaging.
• Shortage response and supply continuity.

A company does not need a new patent to gain share. It can compete through reliable fill-finish capacity, lower landed cost, rapid replenishment, and a product presentation that reduces pharmacy labor.

What generic entry risks exist for lactulose solution?

Patent litigation risk is generally lower than regulatory and commercial execution risk.

Paragraph IV challenges

A Paragraph IV certification could arise if an ANDA applicant identifies an unexpired listed patent covering the reference product. For a mature lactulose solution, the more likely outcome is a certification pathway based on the absence of relevant listed patents or a non-infringement position. The risk cannot be determined from the active ingredient alone; current Orange Book listings and product-specific patents control [4].

Regulatory risks

The principal FDA risks are:

• Failure to match the reference product's dosage form and strength.
• Inadequate impurity characterization.
• Insufficient stability data.
• Inadequate preservative effectiveness or microbial controls.
• Inconsistent lactulose assay.
• Container-closure failures.
• Labeling differences affecting indications, warnings, or dosing.
• Inadequate demonstration of pharmaceutical equivalence.

Commercial risks

Generic entrants face:

• Low unit pricing.
• Limited differentiation in standard bottles.
• Concentrated purchasing by wholesalers and hospitals.
• Inventory exposure from a relatively low-value product.
• Demand volatility when competitors experience shortages.
• Patient reluctance to switch if taste differs.

How does lactulose solution compare with competing constipation products?

Product category	Key advantage	Key limitation relative to lactulose
Lactulose solution	Established efficacy; also used in hepatic encephalopathy	Taste, viscosity, bloating, and dosing burden
Polyethylene glycol	Convenient powder or solution formats; broad constipation use	Does not replace lactulose's established hepatic-encephalopathy role
Sorbitol solution	Low-cost osmotic alternative	Different labeling, tolerability, and clinical positioning
Magnesium salts	Rapid or effective osmotic action in selected patients	Renal and electrolyte considerations
Stimulant laxatives	Convenient tablets and low cost	Different mechanism and tolerability profile
Fiber products	Consumer familiarity and chronic-use positioning	Slower effect and hydration dependence

Lactulose has the strongest commercial differentiation in hepatic encephalopathy, where alternatives may include rifaximin-based regimens and other supportive approaches. In ordinary constipation, the product competes mainly on price, tolerability, convenience, and patient preference.

What licensing deals and commercial opportunities exist?

Publicly visible licensing value is likely to be limited for unmodified lactulose solution. The strongest deal structures are commercial rather than asset-based:

• Regional in-licensing of an approved product.
• Private-label supply agreements.
• Hospital and long-term-care contracts.
• Co-development of unit-dose packaging.
• Supply agreements for pharmaceutical-grade lactulose concentrate.
• Contract manufacturing and fill-finish arrangements.
• Distribution rights for flavored or pediatric-oriented presentations.

Potentially valuable innovations include a stable preservative-free product, a portable unit-dose format, a validated low-color formulation, or packaging that enables accurate titration in home care and institutional settings.

What revenue exposure does lactulose solution create?

Revenue exposure is usually modest per patient but can be durable because lactulose is used chronically in constipation and hepatic encephalopathy. Value depends on channel:

• Retail pharmacy favors bottle economics, reimbursement, and generic substitution.
• Hospitals favor unit-dose packaging, supply reliability, and reduced administration errors.
• Long-term-care facilities favor dosing workflow and predictable procurement.
• Hepatology-focused channels may support higher adherence value because patients can require prolonged treatment.
• International markets may allow broader nonprescription access, depending on local classification.

The commercial opportunity is therefore a scale-and-execution opportunity. Margin expansion is more likely to come from packaging, procurement, and manufacturing efficiency than from a premium active-ingredient claim.

Key Takeaways

• Lactulose solution is a mature small-molecule oral drug with low conventional patent risk.
• The standard formulation is an aqueous 10 g/15 mL solution with limited excipient complexity.
• The most relevant formulation opportunities are taste masking, unit-dose delivery, viscosity control, preservative strategy, and packaging.
• Biosimilar risk is not applicable; generic substitution is the principal competitive threat.
• Paragraph IV litigation is product-specific and should be assessed through current Orange Book listings and patent records.
• Manufacturing know-how, impurity control, low-color production, and reliable supply may provide greater commercial value than new patents.
• Hepatic encephalopathy is the strongest clinical differentiation; constipation is the larger convenience and volume opportunity.
• Licensing opportunities are most credible in regional distribution, private label, contract manufacturing, and differentiated delivery formats.

FAQs

Is lactulose solution an excipient or an active pharmaceutical ingredient?

Lactulose is the active pharmaceutical ingredient. Purified water, flavoring, acidulants, preservatives, and coloring agents may function as excipients depending on the approved product.

Can lactulose solution be reformulated as a tablet?

Yes, but a tablet would require a high active load or a concentrated delivery system because standard dosing can reach 15 to 30 mL or more per administration. An oral solution remains more practical for dose titration.

Is a sugar-free lactulose product commercially feasible?

A conventional sugar-free claim is difficult because lactulose is itself a synthetic disaccharide. A product may reduce certain residual sugars, but claims must distinguish lactulose from excipient sugars and comply with applicable FDA labeling rules.

What is the strongest patent opportunity for lactulose?

The strongest opportunities are likely to involve a technically demonstrated formulation or delivery improvement, such as preservative-free multidose stability, taste-masked unit dosing, impurity reduction, or a specialized container-closure system.

Does lactulose compete directly with rifaximin?

The products can be used in the same hepatic encephalopathy treatment landscape but are not direct formulation substitutes. Lactulose is an osmotic and ammonia-lowering therapy, while rifaximin is an intestinally acting antibiotic. Treatment decisions depend on indication, severity, prior response, and clinical guidelines [2,5].

References

1. U.S. Food and Drug Administration. (n.d.). Lactulose oral solution prescribing information. DailyMed.
2. Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by AASLD and EASL. Hepatology, 60(2), 715-735.
3. U.S. National Library of Medicine. (n.d.). Lactulose solution drug labels. DailyMed.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
5. American Association for the Study of Liver Diseases. (2014). Hepatic encephalopathy in chronic liver disease: Practice guideline. AASLD.